Last reviewed · How we verify
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE — Competitive Intelligence Brief
marketed
Other
Live · refreshed every 30 min
Target snapshot
DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE (DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE) — LUPIN LTD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE TARGET | DAPAGLIFLOZIN, SAXAGLIPTIN MONOHYDRATE | LUPIN LTD | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE CI watch — RSS
- DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE CI watch — Atom
- DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE CI watch — JSON
- DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE alone — RSS
Cite this brief
Drug Landscape (2026). DAPAGLIFLOZIN AND SAXAGLIPTIN MONOHYDRATE — Competitive Intelligence Brief. https://druglandscape.com/ci/dapagliflozin-saxagliptin-monohydrate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing